Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category

Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes

Reporter: Amandeep Kaur, B.Sc., M.Sc.

A recent study reports the development of an advanced AI algorithm which predicts up to five years in advance the starting of type 2 diabetes by utilizing regularly collected medical data. Researchers described their AI model as notable and distinctive based on the specific design which perform assessments at the population level.

The first author Mathieu Ravaut, M.Sc. of the University of Toronto and other team members stated that “The main purpose of our model was to inform population health planning and management for the prevention of diabetes that incorporates health equity. It was not our goal for this model to be applied in the context of individual patient care.”

Research group collected data from 2006 to 2016 of approximately 2.1 million patients treated at the same healthcare system in Ontario, Canada. Even though the patients were belonged to the same area, the authors highlighted that Ontario encompasses a diverse and large population.

The newly developed algorithm was instructed with data of approximately 1.6 million patients, validated with data of about 243,000 patients and evaluated with more than 236,000 patient’s data. The data used to improve the algorithm included the medical history of each patient from previous two years- prescriptions, medications, lab tests and demographic information.

When predicting the onset of type 2 diabetes within five years, the algorithm model reached a test area under the ROC curve of 80.26.

The authors reported that “Our model showed consistent calibration across sex, immigration status, racial/ethnic and material deprivation, and a low to moderate number of events in the health care history of the patient. The cohort was representative of the whole population of Ontario, which is itself among the most diverse in the world. The model was well calibrated, and its discrimination, although with a slightly different end goal, was competitive with results reported in the literature for other machine learning–based studies that used more granular clinical data from electronic medical records without any modifications to the original test set distribution.”

This model could potentially improve the healthcare system of countries equipped with thorough administrative databases and aim towards specific cohorts that may encounter the faulty outcomes.

Research group stated that “Because our machine learning model included social determinants of health that are known to contribute to diabetes risk, our population-wide approach to risk assessment may represent a tool for addressing health disparities.”

Sources:

https://www.cardiovascularbusiness.com/topics/prevention-risk-reduction/new-ai-model-healthcare-data-predict-type-2-diabetes?utm_source=newsletter

Reference:

Ravaut M, Harish V, Sadeghi H, et al. Development and Validation of a Machine Learning Model Using Administrative Health Data to Predict Onset of Type 2 Diabetes. JAMA Netw Open. 2021;4(5):e2111315. doi:10.1001/jamanetworkopen.2021.11315 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780137

Other related articles were published in this Open Access Online Scientific Journal, including the following:

AI in Drug Discovery: Data Science and Core Biology @Merck &Co, Inc., @GNS Healthcare, @QuartzBio, @Benevolent AI and Nuritas

Reporters: Aviva Lev-Ari, PhD, RN and Irina Robu, PhD

https://pharmaceuticalintelligence.com/2020/08/27/ai-in-drug-discovery-data-science-and-core-biology-merck-co-inc-gns-healthcare-quartzbio-benevolent-ai-and-nuritas/

Can Blockchain Technology and Artificial Intelligence Cure What Ails Biomedical Research and Healthcare

Curator: Stephen J. Williams, Ph.D.

https://pharmaceuticalintelligence.com/2018/12/10/can-blockchain-technology-and-artificial-intelligence-cure-what-ails-biomedical-research-and-healthcare/

HealthCare focused AI Startups from the 100 Companies Leading the Way in A.I. Globally

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/01/18/healthcare-focused-ai-startups-from-the-100-companies-leading-the-way-in-a-i-globally/

AI in Psychiatric Treatment – Using Machine Learning to Increase Treatment Efficacy in Mental Health

Reporter: Aviva Lev- Ari, PhD, RN

https://pharmaceuticalintelligence.com/2019/06/04/ai-in-psychiatric-treatment-using-machine-learning-to-increase-treatment-efficacy-in-mental-health/

Vyasa Analytics Demos Deep Learning Software for Life Sciences at Bio-IT World 2018 – Vyasa’s booth (#632)

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/05/10/vyasa-analytics-demos-deep-learning-software-for-life-sciences-at-bio-it-world-2018-vyasas-booth-632/

New Diabetes Treatment Using Smart Artificial Beta Cells

Reporter: Irina Robu, PhD

https://pharmaceuticalintelligence.com/2017/11/08/new-diabetes-treatment-using-smart-artificial-beta-cells/

Read Full Post »

The top 10 medtech M&A deals of 2020

Reporter: Aviva Lev-Ari, PhD, RN

SOURCE

Read Full Post »

National Resilience, Inc. is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption – the Acquisition of Two Premier Biologics Manufacturing Facilities: Boston and in Ontario, Canada

 

Reporter: Aviva Lev-Ari, PhD, RN

Resilience’s new facility, located at 500 Soldiers Field Rd., Boston, MA. (Photo: Business Wire) – The Genzyme-Sanofi Building

 

SAN DIEGO & BOSTON–(BUSINESS WIRE)–Resilience (National Resilience, Inc.), a new company building the world’s most advanced biopharmaceutical manufacturing ecosystem, announced it has acquired two premier commercial manufacturing facilities in North America, joining other facilities already in Resilience’s network to boost total capacity under management to more than 750,000 square feet.

“These locations will serve as hubs for the future of biopharma manufacturing, leading the way and shaping the future of Resilience.”

  • The acquired facilities include a 310,000-square-foot plant in Boston, MA, purchased from Sanofi; and in a separate transaction,
  • a 136,000-square-foot plant in Mississauga, Ontario, Canada.

Both facilities, which currently produce commercial, marketed products, will see significant investments as Resilience adds capacity and capabilities to produce new therapies at these locations. In addition, the company has offered employment to the existing plant staff and intends to add more jobs at each facility.

“We have big plans for these facilities including investing in new capacity, applying new manufacturing technologies, creating jobs and bringing in new customers,” said Rahul Singhvi, Sc.D, Chief Executive Officer of Resilience. “These locations will serve as hubs for the future of biopharma manufacturing, leading the way and shaping the future of Resilience.”

As part of its agreement with Sanofi, Resilience will continue to manufacture a marketed product at the Boston location. The facility plan includes a build out to facilitate multi-modality manufacturing and state-of-the-art quality laboratories to ensure safe, reliable supply to patients. The facility itself is certified ISO 14001 (Environmental management system), OSHAS 18001 (Health & safety management system) and ISO 50001 (Energy management system).​

This is currently the largest of several facilities in Resilience’s growing biologics and advanced therapeutics manufacturing network, with plans to acquire and develop other sites in the U.S. this year. The facility offers 24/7/365 production, multiple 2000L bioreactors capacity and multiple downstream processing trains, with investment in additional capabilities to come.

Our state-of-the-art flexible facility in Mississauga, Ontario, provides upstream, downstream and aseptic fill finish, and is designed to comply with cGMP. The plant has been inspected and approved by multiple regulatory bodies, and handles development and commercialized products.

About Resilience

Resilience (National Resilience, Inc.) is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale. Resilience offers the highest quality and regulatory capabilities, and flexible and adaptive facilities to serve partners of all sizes. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience frees partners to focus on the discoveries that improve patients’ lives.

For more information, visit www.Resilience.com.

Contacts

Ryan Flinn
Head of Communications
Ryan.flinn@Resilience.com
510-207-7616

Read Full Post »

Podcast Episodes by THE EUROPEAN VC

Reporter: Aviva Lev-Ari, PhD, RN

 

Audio files are st:

The European VC

 

EPISODE #5: WILLIAM MCQUILLAN, FOUNDING PARTNER OF A VENTURE FIRM FOR GLOBALLY AMBITIOUS B2B COMPANIES

William is a founding partner of Frontline Ventures. Prior to starting Frontline, he was a founding employee at Ondra, an award-winning investment boutique that went from a 4 person team to 70+ employees in only 18 months. When Frontline was founded, William was 27 years old, making him the youngest VC ever to have raised a fund at that time (2012). Shortly after recording this episode William announced Frontline Fund III.

 

In this episode you will learn:

– How William has built a truly differentiated investment thesis for Frontline’s two funds.

– What William looks for in seed stage startups and why he believes integrity is all important and money cannot be the founder’s main driver.

– How William perceives the effects of Brexit and its implications for their investment strategy and work with startups.

– Why William is a supporter of founders taking a small bit of secondaries.

EPISODE #4: SHOMIT GHOSE, GP OF A SILICON VALLEY FIRM WITH 7 FUNDS UNDER ITS BELT

This episode runs contrary to what the European VC stands for and features an American VC from the Valley. However, the focus is on looking from the outside in, as well as carving out lessons learned from decades of collaboration across the Atlantic. Shomit Ghose is a General Partner of ONSET Ventures, a leading early stage venture firm operating out of Sand Hill Road, in Silicon Valley. With more than 130 startups and 7 funds under its belt, ONSET Ventures is a highly respected firm in the Valley. Shomit is a seasoned VC with multiple IPOs under his belt – both as an investor and as an entrepreneur.

 

In this episode you will learn:

– How the European and American VC landscapes differ and what we can learn from both.

– How to increase your presence and establish collaborations between US and European VCs.

– How to approach building a country-agnostic fund and the role of VCs, LPs and Institutions.

EPISODE #3 MICHAEL HANSEN, CEO OF A LEADING BUSINESS ANGEL ASSOCIATION IN EUROPE

Michael Hansen is the CEO of DanBAN, Denmark’s leading Business Angel Association. DanBAN consist of more than 200 active Angels who collectively invest in more than 30 M€ on an annual basis. Prior to joining DanBAN, Michael was the chief architect behind the sprawling investment environment around the Danish Robotics Cluster which is broadly recognized as one of the very strongest clusters for Robotics companies in Europe, if not the world.

In this episode, you will learn from a true investment cluster builder

– The importance of politicians making brave strategic decisions in promoting cluster development.

– The story of the Danish Robotics Cluster in which the first collaborative robots were hatched, counting with two acquisitions at a valuation of almost 1 billion EUR.

– How to work with national clusters to generate deal flow and fast track deals.

– Collaboration models between Business Angels and VCs.

EPISODE #2 STEPHAN MORAIS, FOUNDER AND MANAGING PARTNER OF A LEADING EARLY-STAGE DEEP TECH VC FIRM

Stephan Morais is the founder and Managing Partner of Indico Capital Partners, a leading early-stage deep tech VC firm. With a diversified background as an investment banker, consultant, entrepreneur and CEO, he has lived in 8 countries and 4 continents over the last 24 years, and acted as and advisor to politicians and European institutions. Prior to founding Indico, Stephan was an Executive Board Member at Caixa Capital, where he led investment rounds of many Portuguese global tech success stories.

In this episode, you’ll learn

– How Stephan tackled raising a VC fund and what to should look for in LPs

– How European VCs can push for policy developments that allow for more capital to be deployed into the industry

– What Europe can learn from other countries and regions

– What learnings Stephan has drawn from running an iberian fund

EPISODE #1 MARC LOHRMANN, MANAGING PARTNER OF A 120 M€ LIFE SCIENCE FUND

Marc Lohrmann is the Managing Partner of Vesalius Biocapital III, a 120 €M venture capital fund investing in late-stage companies in drug development, medical devices, diagnostics and eHealth, across Europe. Prior to joining Vesalius, Marc started eight life sciences companies, worked as an investment manager at a leading corporate VC and worked with several corporate finance boutiques focused on life sciences M&A transactions.

In this episode, you’ll learn

– How VBC III works as a country-agnostic VC fund and the main barriers to more funds investing across Europe.

– How investors without a natural sciences background can create value for Life Sciences companies and why founders find these investors a refreshing element in the board room.

– What Marc would love to change about European VC, what’s important when investing across Europe and what’s next for Marc.

 

 

 

 

SOURCE

https://www.theeuropeanvc.com/?utm_source=Sutardja%20Center%20Contacts&utm_campaign=f20d2f4f55-EMAIL_CAMPAIGN_2019_08_21_04_25_COPY_01&utm_medium=email&utm_term=0_8ae9d85a8f-f20d2f4f55-164676973

Read Full Post »

World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

Reporter: Aviva Lev-Ari, PhD, RN

 

Davos Agenda

https://www.weforum.org/events/the-davos-agenda-2021

 

Adrian Monck, Managing Director, Public Engagement, public.affairs@weforum.org

日本語 | 中文 | عربي

World Leaders to Meet During Davos Agenda in a Crucial Year to Rebuild Trust

  • The Davos Agenda 2021 will convene under the theme: A Crucial Year to Rebuild Trust
  • The World Economic Forum will gather the world’s foremost leaders to address the economic, environmental, social and technological challenges following the COVID-19 pandemic 
  • More than 1,500 business, government and civil society leaders from over 70 countries will set the agenda for a critical year ahead and discuss how to catalyse impact in the rapidly advancing Fourth Industrial Revolution
  • The conclusions from the Davos Agenda week will feed into task forces working on global issues for the upcoming Special Annual Meeting in Singapore
  • For more information, please visit http://www.weforum.org; share on social media using the hashtag #DavosAgenda

Geneva, Switzerland, 18 January 2021 – The World Economic Forum Davos Agenda, taking place virtually on 25-29 January, will bring together the foremost leaders of the world to address the new global situation. Heads of state and government, chief executives and leaders from civil society will convene under the theme: A Crucial Year to Rebuild Trust.

The meeting will focus on creating impact, rebuilding trust and shaping the policies and partnerships needed in 2021.

“In the context of the COVID-19 pandemic, the need to reset priorities and the urgency to reform systems have been growing stronger around the world,” said Klaus Schwab, Founder and Executive Chairman of the World Economic Forum. “Rebuilding trust and increasing global cooperation are crucial to fostering innovative and bold solutions to stem the pandemic and drive a robust recovery. This unique meeting will be an opportunity for leaders to outline their vision and address the most important issues of our time, such as the need to accelerate job creation and to protect the environment.”

The COVID-19 pandemic has demonstrated that no institution or individual alone can address the economic, environmental, social and technological challenges of our complex, interdependent world. The pandemic has accelerated systemic changes that were apparent before its inception. The fault lines that emerged in 2020 now appear as critical crossroads in 2021. The Davos Agenda will help leaders choose innovative and bold solutions to stem the pandemic and drive a robust recovery over the next year.

The five programme themes are:

  1. Designing cohesive, sustainable, resilient economic systems (25 January)
  2. Driving responsible industry transformation and growth (26 January)
  3. Enhancing stewardship of the global commons (27 January)
  4. Harnessing the technologies of the Fourth Industrial Revolution (28 January)
  5. Advancing global and regional cooperation (29 January)

Special addresses from G20 heads of state and government and international organizations will provide crucial insights into a range of important issues in the year ahead. Participants will hear first-hand how these public figures will demonstrate leadership and drive action in areas such as the environment, jobs, and advances in innovation brought by the Fourth Industrial Revolution.

Heads of state and government include:

Xi Jinping, President of the People’s Republic of China; Narendra Modi, Prime Minister of India; Yoshihide Suga, Prime Minister of Japan; Emmanuel Macron, President of France; Angela Merkel, Federal Chancellor of Germany; Ursula von der Leyen, President of the European Commission; Giuseppe Conte, Prime Minister of Italy; Moon Jae-in, President of the Republic of Korea; Alberto Fernández, President of Argentina; Cyril Ramaphosa, President of South Africa; Pedro Sánchez, Prime Minister of Spain; Guy Parmelin, President of the Swiss Confederation and Federal Councillor for Economic Affairs, Education and Research; Ivan Duque, President of Colombia; Carlos Alvarado Quesada, President of Costa Rica; Nana Addo Dankwa Akufo-Addo, President of the Republic of Ghana; Kyriakos Mitsotakis, Prime Minister of Greece; Benjamin Netanyahu, Prime Minister of Israel; Abdullah II ibn Al Hussein, King of the Hashemite Kingdom of Jordan; Paul Kagame, President of Rwanda; Lee Hsien Loong, Prime Minister of Singapore, the host of the World Economic Forum Special Annual Meeting 2021.

Other world leaders are expected to confirm.

Leaders from international organizations, government agencies and central banks include:

António Guterres, Secretary-General, United Nations (UN); Tedros Adhanom Ghebreyesus, Director-General, World Health Organization (WHO); Kristalina Georgieva, Managing Director, International Monetary Fund (IMF); Amina Mohammed, Deputy Secretary-General, United Nations (UN); Achim Steiner, Administrator, United Nations Development Programme (UNDP); Phumzile Mlambo-Ngcuka, Undersecretary-General and Executive Director, United Nations Entity for Gender Equality and the Empowerment of Women (UN WOMEN); Dongyu Qu, Director-General, Food and Agriculture Organization of the United Nations (FAO); Inger Andersen, Executive Director, United Nations Environment Programme (UNEP); Henrietta Fore, Executive Director, United Nations Children’s Fund (UNICEF); David Beasley, Executive Director, United Nations World Food Programme (WFP); Fang Liu, Secretary-General, International Civil Aviation Organization (ICAO); Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA; Angel Gurría, Secretary-General, Organisation for Economic Co-operation and Development (OECD); Mauricio Claver-Carone, President, Inter-American Development Bank (IDB); Guy Ryder, Director-General, International Labour Organization (ILO); Jürgen Stock, Secretary-General, International Criminal Police Organization (INTERPOL); Fatih Birol, Executive Director, International Energy Agency (IEA); Rebecca Fatima Sta Maria, Executive Director, APEC Secretariat (Asia-Pacific Economic Cooperation).

Christine Lagarde, President, European Central Bank; François Villeroy de Galhau, Governor of the Central Bank of France; Andrew Bailey, Governor of the Bank of England.

The private sector will be represented by more than 1,000 leaders from the Forum’s member and partner organizations. Seven of the top ten companies by market capitalization are engaged year-round with the Forum and many will participate in The Davos Agenda week. As a working meeting to advance ongoing project work, more than 500 chief executives and chairpersons will take part in sessions throughout the week.

Leaders from civil society are a critical voice in shaping the agenda. Those taking part in the meeting include:

Seth Berkley, Chief Executive Officer, Gavi, the Vaccine Alliance; Gabriela Bucher, Executive Director, Oxfam International; Sharan Burrow, General Secretary, International Trade Union Confederation (ITUC); Hindou Oumarou Ibrahim, President, Association for Indigenous Women and Peoples of Chad (AFPAT); Marco Lambertini, Director-General, WWF International; Laura Liswood, Secretary-General, Council of Women World Leaders; Delia Ferreira Rubio, Chair, Transparency International; Peter Sands, Executive Director, Global Fund to Fight AIDS, Tuberculosis and Malaria (GF). 

Drawn from over 10,000 civic-minded young leaders, members of the World Economic Forum’s Global Shapers, Young Global Leaders, Technology Pioneers and Social Entrepreneurs communities will bring unique perspectives to The Davos Agenda.

Flagship reports, initiatives, and the latest book on Stakeholder Capitalism 

On January 25, Professor Schwab will release his latest book, titled “Stakeholder Capitalism: A Global Economy that Works for Progress, People and Planet.” It explores how societies can build the future post-COVID, and builds on the Forum’s 50-year-old advocacy of the stakeholder approach.

The World Economic Forum will release its Global Risks Report 2021 on 19 January. The flagship report is an important marker for prioritizing action in public and private sectors in the year ahead.

The Davos Agenda will also mark the launch of several World Economic Forum initiatives to accelerate the race to net-zero emissions, to champion new standards for racial justice, to ensure artificial intelligence is developed ethically and in the global public interest and to close the digital divide. More details on these initiatives and others will be disclosed at the meeting.

Opening Event and Crystal Awards

The meeting will be preceded by the Opening Event, available on YouTube on Sunday 24 January at 19.00 CET, featuring a welcome from Klaus Schwab and a special address by Guy Parmelin, President of the Swiss Confederation, just before the 27th Crystal Awards hosted by Hilde Schwab, Chairperson and Co-founder, Schwab Foundation for Social Entrepreneurship, and the photographer Platon.

The awards will be followed by the world premiere of “See Me: A Global Concert.” The official programme of The Davos Agenda will begin on 25 January.

Notes to editors

Media registration and sign-up

Explore the guide on how to follow and embed sessions on your website here

Watch the livestreamed sessions here

Follow the Forum on Twitter via @wef@davos and join the conversation using #DavosAgenda | Instagram | LinkedIn | TikTok | Weibo | Podcasts

Become a fan of the Forum on Facebook

Read the Forum Agenda also in French | Spanish | Mandarin | Japanese

Check out the Forum’s Strategic Intelligence Platform and Transformation Maps

Watch Forum videos

Learn about the Forum’s impact

Subscribe to Forum news releases and Podcasts

SOURCE

From: “<Adrian Monck>”, World Economic Forum <Public.Affairs@weforum.org>

Reply-To: “<Adrian Monck>”, World Economic Forum <Public.Affairs@weforum.org>

Date: Monday, January 18, 2021 at 9:37 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: World Leaders to meet during Davos Agenda in a crucial year to rebuild trust

Read Full Post »

Venture Summit Virtual Connect West, March 16th -18th 2021 featuring a dedicated Lifesciences / Healthcare Track

 

Leaders in Pharmaceutical Business Intelligence

&

youngStartup Ventures

 

UPDATED on 2/17/2021

Venture Summit Virtual Connect West Early Bird rates were extended to this Thursday, February 18th at midnight (EST). Would it be possible to share the dedicated discount code LPBIVIP again with your network? Included updated social media copy below.

The discount code will still operate when the rates increase but applicants should apply asap to lock in the lowest possible rates. Registration closes around March 11th.

Partial roster of over 170 VCs and Angels Confirmed to Speak and Judge:

Bozena Adamczyk, Investment Director, Truffle Capital | Coleman Adams, Partner, CEVG | Dan Altschuler Malek, Managing Partner, Unovis Asset Management | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | Salman Azhar, Founding Partner & Managing Director, Azhar Private Equity | Afonso Babo, Co-managing director, COREangels Impact | Sion Balass, Partner, The Group Ventures | Assaf Barnea, CEO, Sanara Ventures | Hasan Basrai, Associate, Information Venture Partners | Randy Berholtz, Investor Judge, Mesa Verde Venture Partners | Ned Berman, Senior Associate, Differential Ventures | Reetika Bhardwaj, Associate, ARCH Venture Partners | Udit Bhatnagar, Vice President, McRock Capital | Jason Blumberg, CEO/Managing Partner, Energy Foundry | Christopher Booker, Partner, Frist Cressey Ventures | Alice Brooks, Principal, Khosla Ventures | Alex Brufsky, Venture Partner, 1435 Capital | Edouard Bulteau, Principal, Total Carbon Neutrality Ventures | Ryuk Byun, Associate, Aisling Capital | James Carroll, Managing Partner, CC Angel Investments | Adam Carson, Operating Partner, Point72 Ventures | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Andre Chabaneix, Associate, Blue Bear Capital | Iris Chan, Partner, Mighty Capital | Ray Chan, Managing Director, K5 Ventures | Jonathan Charles, Director, Samsung Catalyst Fund | Elizabeth Cho-Fertikh, Co-Founder & Managing Director, MEDA Angels | Ryan Chou, Investment Associate, JetBlue Technology Ventures | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Darren Cooke, Investor and Board Member, Life Science Angels | Amy Coveny, Managing Partner, Quake Capital | Rick Cutright, Technology Principal, OGCI Climate Investments | Joe Darcy, Principal, IDEA Fund Partners | Rahul Daryanani, Investor, Touchdown Ventures | Timur Davis, Principal, Munich Re Ventures | Angelo Del Priore, Partner, HP Tech Ventures | Jun Deng, Investment Partner, Joyance Partners | Eric Desai, Partner, Greenhouse Capital Partners | Philip Deutch, Partner, NGP ETP | Dixon Doll, Co-Founder & Partner Emeritus, DCM Ventures | Francesco Draetta, Principal, Omega Funds | Vikki Dunn, Operating Partner, Energy Innovation Capital | Amy Dyck, Associate, Framework Venture Partners | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Ali Farahanchi, Managing Director, DHVC | Andrew Felbinger, Investor, Urban Innovation Fund | Manny Fernandez, Angel Investor, SF Angels Group | Mark Fields, Partner, Alsop Louie Partners | Carolin Funk, Investment Director, Blue Bear Capital | Tarik Galijasevic, Managing Director, Allstate Strategic Ventures | Elena Gantvarg, Principal, Flint Capital | Chris Garabedian, CEO, Xontogeny | Daisy Garcia, Investment Analyst, JetBlue Technology Ventures | Joe Garcia, Venture Fellow, Rethink Impact | Selma Gasc, Investment Analyst, 360 Capital | Gary Gershony, Founding General Partner, BayMed Venture Partners | Michal Geva, Co-Founder and Managing Partner, Triventures | Shmuel Gniwisch, Managing Partner/Co-founder, Kli Capital | David Goldberg, General Partner, Alpaca VC | Garrett Goldberg, Partner, Bee Partners | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Emi Gonzalez, Senior Principal, Social Starts | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Deepak Gupta, Managing Partner, Blue Bear Ventures | Katie Hayes, Director, Wittington Ventures | Yashwanth Hemaraj, Partner, Benhamou Global Ventures | Thomas Henry, Co-Founder COO, Eunike Ventures | Robert Hess, Angel Investor, Life Science Angels | David Hornik, Partner, August Capital | Kirsten Horning, Principal, XRC Labs | Galit Horovitz, Co-founder, Welltech1 | Conor Hunt, Principal, 1435 Capital | Noel Jee, Principal, Illumina Ventures | Ben Jen, Managing Director, Ben Jen Holdings | Denis Kalyshkin, Principal, I2BF Global Ventures | Tomas Kemtys, Partner, Contrarian Ventures | Hunter Kettering, VC, Red Cedar Ventures | Maureen Klewicki, Investor, Crosscut Ventures | Howard Ko, Principal, Morpheus Ventures | John-Paul Lake, Managing Partner, Kern Venture Group | Rachel Lauren, Analyst, Bertelsmann Digital Media Investments | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Alicia Lenis, Vice President, Chrysalix Venture Capital | Todd Lewis, VP, Prologis Ventures, Prologis Ventures | Ephraim Lindenbaum, Managing Director, Advance Ventures | Charles Ling, Investment Director, Tsingyuan Ventures | Brian Litvak, Market Development, Aster Capital | Jim Lockheed, Principal, JetBlue Technology Ventures | Patrick Lord, Partner – Fintech, Truffle Capital | Eric Lui, Venture Partner, HCG Global Partners | Vincent Lui, Sr. Director Corporate Ventures, SK Telecom Ventures | Shailendra Mahajan, Managing Director, Maxim Ventures | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Radhika Malik, Investment Manager, Samsung Catalyst Fund | Alex Mayall, Associate, Anthemis Group | Melissa McCracken, Principal, Nextech Invest | Maulik Mehta, Investor, Arc Ventures | David Mendez, Managing Partner, Good Growth Capital | Laurie Menoud, Partner, At One Ventures | Inka Mero, Founder & Managing Partner, Voima Ventures | Pedro Mesquita, Investment Analyst, Mindset Ventures | Khash Mohajerani, Director, BWE LLP | Matt Murphy, Partner, Montage Ventures | Olivia Musmanno, Senior Associate, Quake Capital | Molly O’Shea, Investor, NYL Ventures | Gilbert Ohana, Managing Partner, FinTLV Ventures | Victor Orlovski, Managing Partner, Fort Ross Ventures | Shamik Parekh, Investment Associate, Octopus Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Michael Peri, Senior Vice President, NFP Ventures | Michael Perry, Associate, Link Ventures | Daniel Pianko, Managing Director, Achieve Partners | Patricia Poon, Director, Belmond Capital | Robert Poor, Advisor, Good Growth Capital | Ulrich Quay, Managing Partner, BMW i Ventures | Suraj Rajwani, Managing Partner, DoubleRock LLC | Mark Ralph, Executive Director, Boehringer Ingelheim Venture Fund | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Marie-Christine Razaire, Associate, Northwestern Mutual Future Ventures | Julia Reichelstein, Investor, Piva Capital | John Robinson, Partner, Mazarine Ventures | Carolina Rojas, Ventures Analyst, NFP Ventures | Stephen Roland, Associate, Swiftarc Ventures | Alexander Ross, Investment Director, Illuminate Financial | Joseph Rothman, Venture Partner, AlphaPrime Ventures | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Abinav Sankar, Partner, Sopris Capital | Stephanie Sarelakos, VP, Investments, The Venture Collective | Massimo Schäppi, Partner, Tomahawk .VC | Reese Schroeder, Investor, Allstate Strategic Ventures | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Partner, Fort Ross Ventures | Shounok Sinha, Principal, Venture Investing, Constellation Technology Ventures | Michelle Snyder, Partner, McKesson Ventures | Vivek Soni, Venture Partner, S CAP CleanTech | Peter Sopher, Manager, Clean Energy Ventures | Kumar Sripadam, GP, Elevate Capital | Anish Srivastava, Founder & CEO, Vinaj Ventures | Alexander Starchenko, Managing Partner, First Imagine! Ventures | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Ning Sung, Investor, Sandhill Angels | Daniel Teo, Managing Partner, Hunniwell Lake Ventures | Byron Thom, Principal, Framework Venture Partners | Abhinav Tiwari, General Partner, Owl Capital | Erica Van, Investor, Charles River Ventures | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Joe Vasquez, Venture Partner, Revel Partners | Alexander Vavilov, Investment Manager, iTech Capital | Mark Vreeke, Founder, Chemical Angel Network | Jordan Wahbeh, Managing Partner, SV Venture Group | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Isaiah Washington, Analyst, Insight Partners | Lauren Weston, Associate, Thomvest Ventures | Sarah Wolter, Principal, FinTech Collective | Minjia Wu, Principal, SOSV | Yating Xia, Investor, TCL | Steve Yaskin, Venture Partner, Scale Up Ventures | Juan Zavala, Principal, New Markets Venture Partners | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund | Chen Zhou, Investor, Samsung Catalyst Fund and many more…

Regards,

 

Gil

 

Gil Garalnick

Senior Associate

youngStartup Ventures

 

“Where Innovation Meets Capital”

 

p: 212.202.1002 ext 208

e: gil@youngstartup.com

u: www.youngstartup.com

 

 

UPDATED on 1/21/2021

Leaders in Pharmaceutical Business Intelligence is pleased to announce its sponsorship and invite you to join us at Venture Summit Virtual Connect West, featuring a dedicated Lifesciences / Healthcare Track

Special offer: 20% off Early Bird Rates (Use discount code “LPBIVIP”)

 

* Call for Top Innovators Details below

 

 

Venture Summit Virtual Connect West

Where Innovation Meets Capital

 

March 16th -18th 2021

 

 

Friends,

 

Come meet, interact and network online with more than 1,500 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit Virtual Connect West being held virtually on March 16th-18th 2021, featuring a dedicated Lifesciences / Healthcare track.

 

Whether you’re a Lifesciences /Healthcare startup seeking capital and exposure, or an investor seeking new deals, the Lifesciences / Healthcare track at Venture Summit Virtual Connect West presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, Venture Summit Virtual Connect West will bring together over 1,500 VCs, Corporate VCs, Angel Investors, ‎Industry executives and founders of venture backed, emerging and early stage companies; will feature ‎One-on-One networking (online), more than 150 VCs as speakers/ judges; Venture panels, startup workshops, presentations by more than 100 Top Innovators and ‎Keynotes.

 

Partial roster of over VCs and Angels confirmed to speak and judge:

Bozena Adamczyk, Investment Director, Truffle Capital | Dan Altschuler Malek, Managing Partner, Unovis Asset Management | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | Sion Balass, Partner, The Group Ventures | Randy Berholtz, Senior Advisor, Mesa Verde Venture Partners | Ned Berman, Senior Associate, Differential Ventures | Udit Bhatnagar, Vice President, McRock Capital | Christopher Booker, Partner, Frist Cressey Ventures | James Carroll, Managing Partner, CC Angel Investments | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Darren Cooke, Investor and Board Member, Life Science Angels | Amy Coveny, Managing Partner, Quake Capital | Joe Darcy, Principal, IDEA Fund Partners | Rahul Daryanani, Investor, Touchdown Ventures | Timur Davis, Principal, Munich Re Ventures | Jun Deng, Investment Partner, Joyance Partners | Philip Deutch, Partner, NGP ETP | Dixon Doll, Co-Founder & Partner Emeritus, DCM Ventures | Vikki Dunn, Operating Partner, Energy Innovation Capital | Amy Dyck, Associate, Framework Venture Partners | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Ali Farahanchi, Managing Director, DHVC | Andrew Felbinger, Investor, Urban Innovation Fund | Mark Fields, Partner, Alsop Louie Partners | Carolin Funk, Investment Director, Blue Bear Capital | Elena Gantvarg, Principal, Flint Capital | Gary Gershony, Founding General Partner, BayMed Venture Partners | David Goldberg, General Partner, Alpaca VC | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Emi Gonzalez, Senior Principal, Social Starts | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Katie Hayes, Director, Wittington Ventures | Robert Hess, Angel Investor, Life Science Angels | Kirsten Horning, Principal, XRC Labs | Ben Jen, Managing Director, Ben Jen Holdings | Hunter Kettering, VC, Red Cedar Ventures | Howard Ko, Principal, Morpheus Ventures | Rachel Lauren, Analyst, Bertelsmann Digital Media Investments | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Alicia Lenis, Vice President, Chrysalix Venture Capital | Todd Lewis, VP, Prologis Ventures, Prologis Ventures | Charles Ling, Investment Director, Tsingyuan Ventures | Jim Lockheed, Principal, JetBlue Technology Ventures | Patrick Lord, Partner – Fintech, Truffle Capital | Eric Lui, Venture Partner, HCG Global Partners | Vincent Lui, Sr. Director Corporate Ventures, SK Telecom Americas | Shailendra Mahajan, Managing Director, Maxim Ventures | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Maulik Mehta, Investor, Arc Ventures | David Mendez, Managing Partner, Good Growth Capital | Laurie Menoud, Partner, At One Ventures | Pedro Mesquita, Investment Analyst, Mindset Ventures | Khash Mohajerani, Director, BWE LLP | Matt Murphy, Partner, Montage Ventures | Molly O’Shea, Investor, NYL Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Daniel Pianko, Managing Director, Achieve Partners | Robert Poor, Advisor, Good Growth Capital | Ulrich Quay, Managing Partner, BMW i Ventures | Suraj Rajwani, Managing Partner, DoubleRock LLC | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Marie-Christine Razaire, Associate, Northwestern Mutual Future Ventures | John Robinson, Partner, Mazarine Ventures | Stephen Roland, Associate, Swiftarc Ventures | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Massimo Schäppi, Partner, Tomahawk .VC | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Ratan Singh, Partner, Fort Ross Ventures | Michelle Snyder, Partner, McKesson Ventures | Peter Sopher, Manager, Clean Energy Ventures | Kumar Sripadam, GP, Elevate Capital | Anish Srivastava, Founder & CEO, Vinaj Ventures | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Byron Thom, Principal, Framework Venture Partners | Bernhard Ungerbock, Principal, eQventure | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Joe Vasquez, Venture Partner, Revel Partners | Mark Vreeke, Founder, Chemical Angel Network | Jordan Wahbeh, Managing Partner, SV Venture Group | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Lauren Weston, Associate, Thomvest Ventures | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund and many more…

 

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence has made special arrangement for our network to receive a unique discount of an additional 20% off the existing “early bird” savings. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

 

Register Today & Save Click here http://bit.ly/3840e3D    . (Use promo code “LPBIVIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

 

 

We look forward to seeing you there.

 

Leaders in Pharmaceutical Business Intelligence & youngStartup Ventures

 

 

 

Leaders in Pharmaceutical Business Intelligence is pleased to announce its sponsorship and invite you to join us at Venture Summit Virtual Connect West, featuring a dedicated Lifesciences / Healthcare Track

Special offer: 20% off Early Bird Rates (Use discount code “LPBIVIP”)

 

* Call for Top Innovators Details below

  

Venture Summit Virtual Connect West

Where Innovation Meets Capital

 

March 16th -18th 2021

Register Today & Save

Click here http://bit.ly/3840e3D   

(Use promo code “LPBIVIP”)

Friends,

 

Come meet, interact and network online with more than 1,500 VCs, Corporate VCs, angel investors, industry execs and founders of venture backed, emerging and early stage companies at the prestigious Venture Summit Virtual Connect West being held virtually on March 16th-18th 2021, featuring a dedicated Lifesciences / Healthcare track.

Whether you’re a Lifesciences /Healthcare startup seeking capital and exposure, or an investor seeking new deals, the Lifesciences / Healthcare track at Venture Summit Virtual Connect West presented by youngStartup Ventures – is the event of the year you won’t want to miss. 

A highly productive venture conference, Venture Summit Virtual Connect West will bring together over 1,500 VCs, Corporate VCs, Angel Investors, ‎Industry executives and founders of venture backed, emerging and early stage companies; will feature ‎One-on-One networking (online), more than 150 VCs as speakers/ judges; Venture panels, startup workshops, presentations by more than 100 Top Innovators and ‎Keynotes.

 

Partial roster of VCs and Angels confirmed to speak and judge:

Bozena Adamczyk, Investment Director, Truffle Capital | Doug Atkin, Co-Founder, Managing Partner, Communitas Capital Partners | James Carroll, Managing Partner, CC Angel Investments | Kathryn Cartini, Co-founder / Partner, Chloe Capital | Diana Ciobanete, Program Director, Commons Accel | Xiaolei Cong, Vice President, Citi Ventures | Timur Davis, Principal, Munich Re Ventures | Sara Enan, Investment Associate, Global Ventures | Michelle Fan, Founder, Wharton Alumni Angel Network | Andrew Felbinger, Investor, Urban Innovation Fund | Gary Gershony, Founding General Partner, BayMed Venture Partners | Lizzy Goldman, Investment Analyst, Olive Tree Ventures | Jay Goss, General Partner, Wavemaker Three-Sixty Health | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | John Gu, Principal, Spring Mountain Capital | Kirsten Horning, Principal, XRC Labs | Hunter Kettering, VC, Red Cedar Ventures | Rachel Lauren, Analyst, BDMI | Randall LaVeau, Partner, BOSS Capital Partners | James Lee, Investment Director, Photonfund | Sarah Leners, Senior Associate, Bull City Venture Partners | Tai Mai, Investment Fellow, MEDA Angels | Shervin Majd, Angel Investor, Life Science Angels | Matt Murphy, Partner, Montage Ventures | Hirak Parikh, Fund Manager, Michigan Biomedical Venture Fund | Chris Park, Investment Director, UL Ventures | Krish Ramadurai, Partner, Harmonix Fund | Ashley Ramirez, Chief of Staff and Investor, Halogen Ventures | Amit Rathore, Founding Partner, AwakeVC | Vincent Ruinet, Investment Director, ENGIE New Ventures | Igor Ryabenkiy, Managing Partner, AltaIR Capital | Brian Schuman, Investment Professional, PepsiCo Technology Ventures | Simon Sharp, Principal, Global Ventures | Ratan Singh, Partner, Fort Ross Ventures | Michelle Snyder, Partner, McKesson Ventures | Peter Sopher, Manager, Clean Energy Ventures | Anish Srivastava, Founder & CEO, Vinaj Ventures | Nia Stefani, CEO, Xnergy Financial | Nancy Sullivan, CEO and Managing Director, Illinois Ventures | Haolin Sung, Managing Partner, Chaperone Investment | Bernhard Ungerbock, Principal, eQventure | Grant Van Cleve, Managing Partner, Hangar 75 Ventures | Jennifer Vancini, General Partner, Mighty Capital | Brian Walsh, Head, WIND Ventures | Tobi Walter, Principal, Cofounders Capital | Stephanie Zepeda, Principal, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund and many more…

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence has made special arrangement for our network to receive a unique discount of an additional 20% off the existing “early bird” savings. This conference will be attended by the best people in the industry. Please register early to avoid disappointment.

 

Register Today & Save Click here http://bit.ly/3840e3D   

(Use promo code “LPBIVIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

  

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here. 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

  

We look forward to seeing you there.

 

Leaders in Pharmaceutical Business Intelligence

&

youngStartup Ventures

 

 

 

 

 

LinkedIn

Leaders in Pharmaceutical Business Intelligence invites you to join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit Virtual Connect West being held on March 16th– 18th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Whether you are a Lifesciences / Healthcare investor seeking access to new early stage deals, or a CEO or Founder of a new venture looking for funding, visibility and growth, Venture Summit | Virtual Connect is one event you won’t want to miss.

 

Twitter

Join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit Virtual Connect West being held on March 16th– 18th 2021. Dedicated Lifesciences/Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Where do #startups connect with over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators? #VSVC Venture Summit Virtual Connect West being held on March 16th – 18th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register at  http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

Facebook

Leaders in Pharmaceutical Business Intelligence invites you to join over 150 leading VCs, Corp VCs, Angel Investors and over 100 Top Innovators at #VSVC Venture Summit | Virtual Connect West being held on March 16th – 18th 2021. Dedicated Lifesciences / Healthcare Track, One-on-One (zoom) investor meetings, 2 days of content including timely panel discussions, workshops and an inspiring keynotes. Register here today to confirm your spot: http://bit.ly/3840e3D and save an extra 20% off Early Bird Rates with Discount Code: LPBIVIP.

 

 

Read Full Post »

Biomolecular Condensates: A new approach to biology originated @MIT – Drug Discovery at DewPoint Therapeutics, Cambridge, MA gets new leaders, Ameet Nathwani, MD (ex-Sanofi, ex-Novartis) as Chief Executive Officer and Arie Belldegrun, PhD (ex-Kite Therapeutics) on R&D

Curator & Reporter: Aviva Lev-Ari, PhD, RN

 

Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech

A new approach to biology

“The real voyage of discovery consists, not in seeking new landscapes, but in having new eyes.” Marcel Proust

Starting with the study of P granules in C.elegans embryos in 2009, Tony Hyman, working with his collaborators like Frank Julicher, Cliff Brangwynne, Simon Alberti, Mike Rosen, and Rohit Pappu, began to unravel the mysteries of biomolecular condensates. These scientists realized that P granules behave like liquid droplets that form by phase separation (think of oil droplets in salad dressing) and called them condensates.

In subsequent studies, they found to their surprise that many compartments inside cells had the behavior of condensates: they are liquid-like and form by phase separation.

Inspired by the work of Tony and his colleagues, Richard Young, Phillip Sharp, and Arup Chakraborty at MIT applied these approaches to the study of gene expression, similarly shedding light on many important questions in gene control.

a video thumbnail

 

Press releases and Dewpoint in the news

 
  • Dewpoint Therapeutics Appoints Ameet Nathwani as Chief Executive Officer

    Dewpoint

  • New York Times interviews Rick Young and Amy Gladfelter on the role of condensate “droplets” in COVID-19

    New York Times

  • Dewpoint Therapeutics raises $77 million to go after ‘undruggable’ diseases

    Boston Globe

  • Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech

    Endpoint News

  • Dewpoint Therapeutics to put ‘pedal to the metal’ with $77M round

    FierceBiotech

  • Dewpoint Therapeutics Raises $77M Series B Financing to Advance the Development of Drugs That Target Biomolecular Condensates

    Dewpoint

  • 21 biotech startups that are set to take off, according to top VCs

    Business Insider

  • Proteins — and labs — coming together to prevent Rett Syndrome

    Whitehead Institute

  • Dewpoint Therapeutics Collaborates with Merck to Evaluate Novel Approach for the Treatment of HIV

    Dewpoint

  • Discovery of how cancer drugs find their targets could lead to a new toolset for drug development

    Whitehead Institute

SOURCE

https://dewpointx.com/news/

Other related article published in this Online Open Access Scientific Journal include: 

Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

https://pharmaceuticalintelligence.com/2017/10/04/economic-potential-of-a-drug-invention-prof-zelig-eshhar-weitzman-institute-registered-the-patent-versus-a-cancer-drug-in-clinical-trials-car-t-as-a-case-in-point-developed-by-kite-pharma-unde/

Read Full Post »

Tweet Collection by @pharma_BI and @AVIVA1950 and Re-Tweets for e-Proceedings 14th Annual BioPharma &amp; Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

 

e-Proceedings 14th Annual BioPharma & Healthcare Summit, Friday, September 4, 2020, 8 AM EST to 3-30 PM EST – Virtual Edition

Real Time Press Coverage: Aviva Lev-Ari, PhD, RN

Founder & Director, LPBI Group

https://pharmaceuticalintelligence.com/2020/07/28/14th-annual-biopharma-healthcare-summit-friday-september-4-2020-8-am-est-to-3-30-pm-est-virtual-edition/

 

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Hal Barron, Chief Scientific Officer and President R&D, GlaxoSmithKline GWAS not easy to find which gene drives the association  Functional Genomics gene by gene with phenotypes using machine learning significant help

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Hal Barron, Chief Scientific Officer and President R&D, GSK GWAS not easy to find which gene drives the association  Functional Genomics gene by gene with phenotypes using machine learning significant help

Srihari Gopal
@sgopal2

Enjoyed hearing enthusiasm for Neuroscience R&D by Roy Vagelos at #USAIC20. Wonderful interview by Mathai Mammen

Image

1
2
Show this thread

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Nina Kjellson, General Partner, Canaan Data science is a winner in Healthcare Women – Data Science is an excellent match

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Arpa Garay, President, Global Pharmaceuticals, Commercial Analytics, Merck & Co. Data on Patients and identification who will benefit fro which therapy  cultural bias risk aversion

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Najat Khan, Chief Operating Officer, Janssen R&D Data Sciences, Johnson & Johnson Data Validation  Deployment of algorithms embed data by type early on in the crisis to understand the disease

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Sastry Chilukuri, President, Acorn AI- Medidata Opportunities in Data Science in Paharma COVID-19 and Data Science

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Maya Said, Chief Executive Officer, Outcomes4Me Cancer patients taking change of their care Digital Health – consumerization of Health, patient demand to be part of the decision, part the information FDA launched a Program Project Patient Voice

USAIC
@USAIC

We’re taking a quick break at #USAIC20 before our next panel on rare diseases starts at 12:20pm EDT. USAIC would like to thank our Sponsors and Partners for supporting this year’s digital event.

Image

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Roy Vagelos, Chairman of the Board, Regeneron HIV-AIDS: reverse transcriptase converted a lethal disease to a chronic disease, tried hard to make vaccine – the science was not there

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Roy Vagelos, Chairman of the Board, Regeneron Pharmaceuticals Congratulates Big Pharma for taking the challenge on COVID-19 Vaccine, Antibody and anti-viral Government funding Merck was independent from Government – to be able to set the price

1

Dr Kapil Khambholja
@kapilmk

Christopher Viehbacher, Gurnet Point Capital touches very sensitive topic at #USAIC20 He claims that we are never going to have real innovation out of big pharma! Well this isn’t new but not entirely true either… any more thoughts?
1
1
Show this thread

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Daphne Zohar, Founder & CEO, PureTech Health Disease focus, best science is the decision factors

1

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Christopher Viehbacher, Managing Partner, Gurnet Point Capital Dream of every Biotech – get Big Pharma coming to acquire and pay a lot Morph and adapt

anju ghangurde
@scripanjug

Biogen’s chair Papadopoulos big co mergers is an attempt to solve problems; typically driven by patent expirations.. #usaic20

2

anju ghangurde
@scripanjug

Chris Viehbacher/Gurnet Point Capital on US election: industry will work with whoever wins; we’ll have to ‘morph & adapt’ #usaic20

1

Dr Kapil Khambholja
@kapilmk

of

talks about various philosophies and key reasons why certain projects/molecules are killed early. My counter questions- What are chances of losing hope little early? Do small #biopharma publish negative results to aid to the knowledge pool? #USAIC20

Image

2
2
Show this thread

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute DNA repair and epignetics are the future of medicine

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute COlonorectal cancer is increasing immuno therapy 5 drugs marketed 30% cancer patients are treated early detection key vs metastatic 10% of cancer are inherited treatment early

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Rehan Verjee, President, EMD Serono Charities funding cancer research – were impacted and resources will come later and in decreased amount New opportunities support access to Medicine improve investment across the board

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Philip Larsen, Global Head of Research, Bayer AG Repurposing drugs as antiviral from drug screening innovating methods Cytokine storm in OCVID-19 – kinase inhibitors may be antiviral data of tested positive allows research of pathway in new ways

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber 3,000 Telemedicine session in the first week of the Pandemic vs 300 before – patient come back visits patient happy with Telemedicine team virtually need be reimbursed same rate working remotely

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School New normal as a result of the pandemic role of personalized medicine

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Rehan Verjee, President, EMD Serono entire volume of clinical trials at Roche went down same at EMD delay of 6 month, some were to be initiated but was put on hold Charities funding cancer research were impacted and resources will come later smaller

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Laurie Glimcher, President & CEO, Dana-Farber Cancer Institute Dana Farber saw impact of COVID-19 on immunosuppressed patients coming in for Cancer Tx – switch from IV Tx to Oral 96% decrease in screenings due to Pandemic – increase with Cancer

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Pharma’s obligation for next generations requires investment in R&D vs Politicians running for 4 years Patients must come first vs shareholders vs R&D investment in 2011

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Antibiotic research at Merck – no market incentives on pricing for Merck to invest in antibiotics people will die from bacterial resistance next pandemic be bacterial

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Kenneth Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co. Strategies of Merck = “Medicine is for the People not for Profit” – Ketruda in India is not reembureable in India and million are in need it Partnership are encouraged

Dr Kapil Khambholja
@kapilmk

Chairman Stelios Papadopoulos asks #KennethFrazier if wealthy nations will try to secure large proportion of #COVID19 drugs/vaccines. #KennethFrazie rightly mentions: pharma industry’s responsibility to balance the access to diff countries during pandemic. #USAIC20

1
3
Show this thread

Dr Kapil Khambholja
@kapilmk

Almost 60% participants at #USAIC20 feel that MNCs are more likely to run their #clinicalTrials in #INDIA seeing changing environment here, reveals the poll. Exciting time ahead for scientific fraternity as this can substantially increase the speed of #DrugDevelopment globally

Clapping hands sign

Image

1
1
Show this thread

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health Vaccine in clinical trials, public need to return for 2nd shot, hesitancy Who will get the Vaccine first in the US  most vulnerable of those causing transmission Pharma’s risk

4

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr. Barry Bloom, Professor & former Dean, Harvard School of Public Health Testing – PCR expensive does not enable quick testing is expensive result come transmission occurred Antibody testing CRISPR test based Vaccine in clinical trials

1

Aviva Lev-Ari
@AVIVA1950

#USAIC20 Dr Andrew Plump, President of R&D, Takeda Pharmaceuticals COllaboration effort around the Globe in the Pandemic therapy solutions including Vaccines

Read Full Post »

2020 World Medical Innovation Forum – COVID-19, AI  – Life Science and Digital Health Investments, MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

 

 

 

Life science and digital health investments have continued at a strong pace during the COVID-19 crisis. Senior investment leaders discuss what to expect. Will:

  • social distancing affect deal making?
  • key asset categories remain strong – venture, private equity, public offerings, acquisitions?
  • valuations hold up in some categories while others fall?

Moderator: Roger Kitterman, VP, Venture and Managing Partner, Partners Innovation Fund, Mass General Brigham


Jan Garfinkle
, Founder & Manager Partner, Arboretum Ventures, Chair NVCA

Phillip Gross, Managing Director, Adage Capital Management

Christopher Viehbacher, Managing Partner, Gurnet Point Capital

 

VIEW VIDEOS from the event

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Date: Tuesday, May 12, 2020 at 6:48 AM

To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Subject: REGISTRANT RECAP | World Medical Innovation Forum  

 

Dear World Forum Attendee, 

On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that  will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators.  As promised, we  wanted to also share visual Forum session summaries.  You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning

We hope you will join us for the 2021 Forum!  

Thanks again, Chris

e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/04/22/world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-monday-may-11-815-a-m-515-p-m-et/

Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/05/11/tweets-retweets-2020-world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-mond/

Read Full Post »

The ”Disruptive Dozen” – Harnessing Technology to Reduce Health Disparities: Twelve mostly likely to have significant impact on healthcare by end of 2021.

 

2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

 

 

 

https://worldmedicalinnovation.org/2020-disruptive-dozen/

VIEW VIDEOS from the event

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Date: Tuesday, May 12, 2020 at 6:48 AM

To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Subject: REGISTRANT RECAP | World Medical Innovation Forum  

 

Dear World Forum Attendee, 

On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that  will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators.  As promised, we  wanted to also share visual Forum session summaries.  You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning

We hope you will join us for the 2021 Forum!  

Thanks again, Chris

e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/04/22/world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-monday-may-11-815-a-m-515-p-m-et/

Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/05/11/tweets-retweets-2020-world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-mond/

2020 Disruptive Dozen

The ”Disruptive Dozen” results from interviews of one hundred Mass General Brigham senior Harvard faculty followed by a rigorous selection process to identify the twelve mostly likely to have significant impact on healthcare by end of 2021.

Rochelle Walensky, MD

Chief, Infectious Disease, MGH; Professor of Medicine, Harvard Medical School

1.

Battling COVID-19: Maps, Technology, and AI

Mapping the spread of infectious diseases within communities is more important than ever as the novel coronavirus continues to sweep across the globe. Researchers are harnessing AI, technology, and advanced data analytics to map the spread of COVID-19 and identify those infected with the virus.

Watch the #1 disruptive technology in a series of 12.

Thomas Sequist, MD

Chief Patient Experience and Equity Officer, PHS; Professor of Medicine and Health Care Policy, Harvard Medical School

2.

Harnessing Technology to Reduce Health Disparities

Health is determined not just by genes, diet, and exercise, but also by the environments where people live, learn, work, and play. New technologies are emerging to help reduce health disparities and improve health outcomes.

Watch the #2 disruptive technology in a series of 12.

Orhun Muratoglu, PhD

Alan Gary Scholar, Director Harris Orthopaedics Lab, MGH; Professor, Harvard Medical School

4.

Solving the Problem of Infection in Total Joint Replacements

Total joint replacement is an increasingly common procedure. For most patients, recovery is uneventful and lasts a few months, but some experience a much more complicated and painful journey due to infection in the artificial joint. Find out how researchers are harnessing technology to help address this problem.

 

Watch the #4 disruptive technology in a series of 12.

Calum MacRae, MD, PhD

Vice Chair for Scientific Innovation, Department of Medicine, BH; Associate Professor of Medicine, Harvard Medical School

3.

Digital Management of Chronic Disease

Chronic diseases are a major challenge for patients and health care systems alike. In 2016, the U.S. spent over a trillion dollars caring for patients with heart disease, diabetes, cancer and other chronic conditions. Find out how technology could help improve care for these patients — and lower costs.

 

Watch the #3 disruptive technology in a series of 12.

David Scadden, MD

Director, Center for Regenerative Medicine, MGH; Co-Director, Harvard Stem Cell Institute; Gerald and Darlene Jordan Professor of Medicine, Harvard Medical School

7.

New Therapeutic Options for Sickle Cell Disease

Millions of people worldwide suffer from sickle cell disease. While the cause of this debilitating blood disorder has been known for half a century, only two drugs are currently available to treat it. New developments are on the horizon that could help transform the management of a disease that has too often been overlooked.

Watch the #7 disruptive technology in a series of 12.

Patricia Musolino, MD, PhD

Co-Director Pediatric Cerebrovascular Service, MGH; Assistant Professor, Harvard Medical School

6.

Gene Therapies Transform Treatment of Rare, Devastating Diseases

The emergence of the first gene therapies for clinical use signaled a watershed moment in the history of medicine. This treatment modality will do ever more in the coming year for patients, especially those with rare genetic conditions.

Watch the #6 disruptive technology in a series of 12.

Joan Miller, MD

Chief of Ophthalmology, MEE and MGH; Ophthalmologist-in-Chief, BH; David Glendenning Cogan Professor of Ophthalmology and Chair, Department of Ophthalmology, Harvard Medical School

5.

New Tools to Help Aging Eyes and Ears

Like many parts of the body, the eyes and ears can deteriorate with age, making them vulnerable to disease and loss of sensory functions. Find out how new technologies and treatments could help patients and clinicians better protect these organs from age-related decline.

Watch the #5 disruptive technology in a series of 12.

Astrid Weins, MD, PhD

Associate Pathologist, Brigham Health; Assistant Professor, Pathology, Harvard Medical School

10.

Making Cells Larger to See Them More Clearly

Visualizing cells at high-resolution is a cornerstone of modern biology and medicine. For more than a century, as scientists yearned to observe biological structures with greater power and clarity, they built more advanced microscopes. Yet today, even those sophisticated tools have limits. See how researchers are developing a innovative new approach to cell visualization.

Watch the third disruptive technology in a series of 12.

Dennis Selkoe, MD

Co-Director of the Ann Romney Center for Neurologic Diseases, Brigham Health; Vincent and Stella Coates Professor of Neurologic Diseases, Harvard Medical School

9.

First Disease-Modifying Therapy for Alzheimer’s Disease

The world lacks a meaningful treatment for Alzheimer’s disease, a progressive, debilitating neurodegenerative condition that affects millions across the globe. But that could change later this year, when the FDA is expected to weigh in on a novel drug that targets clumps of protein in the brain known as amyloid plaques. If approved, the drug would mark the first disease-modifying therapy for Alzheimer’s disease.

Watch the fourth disruptive technology in a series of 12.

Leonardo Riella, MD, PhD

Medical Director, Vascularized Composite Tissue Transplantation, Brigham Health; Associate Physician, Harvard Medical School

8.

Keeping Transplant Organs Fresher for Longer

Over 120,000 people in this country are now waiting for an organ transplant. What if it were possible to increase the time that organs can be safely stored outside the body prior to transplantation? Scientists are working to drive innovation in this area in an effort to expand the pool of donor organs available for those who need them.

Watch the fifth disruptive technology in a series of 12.

Read Full Post »

Older Posts »